Short Interest in Fulgent Genetics Rises 38.7%

Biotech firm sees significant increase in shares sold short as stock price declines

Mar. 29, 2026 at 7:07pm

Got story updates? Submit your updates here. ›

An extreme close-up of various genetic testing instruments and machinery, conveying the complex, high-tech nature of Fulgent Genetics' operations without using any text or identifiable elements.The sophisticated genetic testing technology powering Fulgent Genetics' diagnostic services faces increasing competitive pressures.Temple City Today

Fulgent Genetics, Inc. (NASDAQ:FLGT) saw a large 38.7% increase in short interest during March, with 2,135,898 shares now sold short, representing 10.2% of the company's total shares outstanding. The short-interest ratio, based on the stock's average daily trading volume, is currently 2.2 days.

Why it matters

The rise in short interest suggests investors are betting against Fulgent Genetics, likely due to the company's declining stock price. This could indicate growing skepticism about the biotech firm's long-term prospects, especially as it faces increased competition in the genetic testing market.

The details

Fulgent Genetics, a California-based provider of genetic testing and diagnostic services, has seen its stock price fall from a 52-week high of $31.04 to around $15.59 as of the latest trading session. The company's revenue and earnings have also missed analyst expectations in recent quarters, contributing to the bearish sentiment.

  • As of March 13th, 2,135,898 Fulgent Genetics shares were sold short.
  • This represents a 38.7% increase from the 1,540,495 shares sold short as of February 26th.

The players

Fulgent Genetics, Inc.

A California-based company specializing in high-complexity genetic testing and diagnostic services, operating CAP- and CLIA-certified laboratories.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Fulgent Genetics' upcoming earnings reports and any updates on the company's competitive positioning in the genetic testing market.

The takeaway

The rise in short interest in Fulgent Genetics reflects growing skepticism about the company's long-term prospects, as it faces increased competition and struggles to meet analyst expectations. This could signal a challenging road ahead for the biotech firm as it seeks to maintain its market share and profitability.